

21

ABSTRACT

Background:

23 The Coronavirus Disease of 2019 (COVID-19) has impacted the health and day-
24 to-day life of individuals, especially the elderly and people with certain pre-existing
25 medical conditions, including cancer. The purpose of this study was to investigate how
26 COVID-19 impacted access to cancer screenings and treatment, by studying the
27 participants in the Multiethnic Cohort (MEC) study.

Methods:

29 The MEC has been following over 215,000 residents of Hawai'i and Los Angeles
30 for the development of cancer and other chronic diseases since 1993-1996. It includes
31 men and women of five racial and ethnic groups: African American, Japanese American,
32 Latino, Native Hawaiian, and White. In 2020, surviving participants were sent an
33 invitation to complete an online survey on the impact of COVID-19 on their daily life
34 activities, including adherence to cancer screening and treatment. Approximately 7,000
35 MEC participants responded. A cross-sectional analysis was performed to investigate
36 the relationships between the postponement of regular health care visits and cancer
37 screening procedures or treatment with race and ethnicity, age, education, and
38 comorbidity.

Results:

40 Women with more education, women with lung disease, COPD, or asthma, and
41 women and men diagnosed with cancer in the past 5 years were more likely to
42 postpone any cancer screening test/procedure due to the COVID-19 pandemic. Groups

43 less likely to postpone cancer screening included older women compared to younger
44 women and Japanese American men and women compared to White men and women.

45 **Conclusions:**

46 This study revealed specific associations of race/ethnicity, age, education level,
47 and comorbidities with the cancer-related screening and healthcare of MEC participants
48 during the COVID-19 pandemic. Increased monitoring of patients in high-risk groups for
49 cancer and other diseases is of the utmost importance as the chance of undiagnosed
50 cases or poor prognosis is increased as a result of delayed screening and treatment.

51 **Funding:**

52 This research was partially supported by the Omidyar 'Ohana Foundation and
53 grant U01 CA164973 from the National Cancer Institute.

54

55

INTRODUCTION

56 The highly contagious Coronavirus Disease of 2019 (COVID-19) has impacted
57 the health and day-to-day life of individuals, especially the elderly and people with
58 certain preexisting medical conditions, including cancer. COVID-19 was declared a
59 worldwide pandemic on March 11, 2020, after its discovery in late December 2019. As
60 of January 30, 2023, 6,831,427 deaths had been reported among 670,507,704 cases
61 worldwide.¹ Due to the rapid spread and high infectivity rates, stay-at-home orders were
62 decreed to allow for physical distancing and self-isolation. Populations at high risk of
63 contracting COVID-19 and developing severe illness were the elderly and people of all
64 ages with pre-existing medical conditions (such as diabetes, high blood pressure, heart
65 disease, lung disease, or cancer).²

66 Cancer patients were not only at a higher risk of severe illness from COVID-19
67 but changes in cancer care were also reported. One example is the finding of the
68 COVID-19 and Cancer Outcomes Study, which is a multicenter prospective cohort study
69 comprised of adult patients with a current or history of hematological malignancy or
70 invasive solid tumor, who were scheduled for an outpatient medical oncology visit at the
71 Tisch Cancer Institute in New York City or the Dana-Farber Cancer Institute in Boston.
72 Researchers found that 10% of patients in the cohort had treatment delayed during the
73 pandemic and, of that subset, 48% had treatment delayed due to a COVID-19
74 diagnosis.³ In the United States, COVID-19 disproportionately affected racial and ethnic
75 minorities, particularly African Americans, with an observed two-fold higher rate of
76 hospitalization and a greater than two-fold higher rate of death, as compared to Non-
77 Hispanic Whites.⁴ The disparity seen with COVID-19 was consistent with patterns of

78 disparities observed for cancer; it is well-documented that 5-year survival rates for
79 multiple cancers are lower in African Americans compared to White Americans. While
80 cancer is a multifactorial disease that is influenced by genetic and environmental factors,
81 COVID-19 is an infectious disease that is enabled by the cellular expression of
82 angiotensin-converting enzyme 2 (ACE2) receptors. However, preexisting comorbidities,
83 socioeconomic disadvantages, living conditions, health literacy, and access to health
84 care appear to fuel underlying risks for both cancer and COVID-19 disparities.⁴

85 In addition, the pandemic has affected access to cancer screenings, especially
86 for colorectal cancer (CRC) and breast cancer. The recommendation for CRC screening
87 among average-risk adults aged 50 to 75 years is to undergo an annual fecal
88 immunochemical test (FIT) or colonoscopy every 10 years.⁵ Screening and appropriate
89 follow-up can reduce incidence and mortality, which is important because CRC is the
90 second leading cause of cancer death in the United States.⁶ One study found that CRC
91 screening rates are particularly low in Hispanic and Asian American adults, recent
92 immigrants, those with low incomes, and the uninsured.⁶ During the COVID-19
93 pandemic, colorectal cancer screenings were reported to have dropped by 84.5% at a
94 network of 20 United States institutions with more than 28 million patients.⁷

95 For breast cancer, which is the most common non-cutaneous malignancy and
96 the 2nd most lethal tumor among women in the US, the recommendation is biennial
97 mammography in women ages 50 to 74 years.⁵ In the MEC, Native Hawaiian
98 participants have the highest risk of breast cancer, followed by Japanese American and
99 White participants.⁸ Nationwide, the breast cancer mortality rate is 40% higher for
100 African American patients compared with White patients.⁹ During the COVID-19

101 pandemic, breast cancer screenings dropped by 89.2% at a network of 20 United States
102 institutions with more than 28 million patients.⁷

103 Lastly, studies have suggested that educational attainment is associated with
104 adherence to cancer screening. For breast cancer, a positive association was found
105 between education level and adherence to mammography screening.¹⁰ For colorectal
106 cancer, a study on United States veterans aged 50-75 years concluded that both
107 education and income show a statistically significant dose-dependent direct association
108 with screening.¹¹

109 In summary, COVID-19 has impacted medical care delivery, access to cancer
110 screening, and the day-to-day life of individuals worldwide. However, the full impact of
111 the pandemic on cancer screenings and cancer care is not entirely known. The purpose
112 of this cross-sectional study was to understand how COVID-19 affected access to
113 cancer screening and treatment, by studying the participants in the Multiethnic Cohort
114 (MEC) study.

115

METHODS

116 **Study Population**

117 The Multiethnic Cohort (MEC) was established in 1993 – 1996 at the University
118 of Hawai'i Cancer Center (UHCC) and the University of Southern California (USC) with
119 the goals of elucidating lifestyle and genetic risk factors responsible for explaining the
120 ethnic/racial disparities that exist for cancer and other chronic diseases.¹² The cohort
121 has followed over 215,000 residents of Hawai'i and Los Angeles, aged 45 to 75 years
122 old at recruitment, and includes men and women of five main ethnic and racial origins:
123 African American, Japanese American, Latino, Native Hawaiian, and White. Participants
124 entered the cohort by returning a 26-page mailed questionnaire. They also were sent
125 follow-up questionnaires every five years. Disease ascertainment was primarily
126 conducted by linking the cohort to SEER cancer registries, death certificate registries,
127 CA hospital discharge diagnoses, and Medicare. Approximately 100,000 MEC members
128 (median age: 82) were still alive as of 2019. Demographics (i.e., race/ethnicity,
129 maximum years of education attained, birthplace), pre-existing and incident disease
130 outcomes, and lifestyle risk factors were available from the MEC database.

131 **Study Design**

132 In May 2020, MEC participants were invited to participate in an online survey
133 (implemented in Qualtrics) on the impact of COVID-19 on their everyday life and health-
134 related behaviors. Emails were sent to over 39,000 and a letter to ~100,000 MEC
135 participants. The initial and a second invitation were sent to all living MEC participants,
136 while a third invitation was sent to those who were 75 or younger. A paper survey was
137 provided if requested. Participants registered online by providing their Email Address,

138 First name, Middle name, Last name, Sex, Birth year, and Zip Code. The entered data
139 linked each participant back to the MEC database. A Spanish registration page was
140 available for registration in Spanish. Each participant was sent a unique identifier and
141 login to answer the survey online. Participants who answered the baseline survey were
142 invited to fill out a weekly, then, monthly shorter follow-up online survey (Supplementary
143 Figure 1). Paper follow-up surveys were not available. The surveys started in May 2020
144 and ended in April 2021. The last baseline survey (the last opportunity to enter the
145 study) was collected on September 25, 2020.

146 **Statistical Analysis**

147 All baseline surveys with at least 50% completion were used for this analysis.
148 Descriptive statistics were utilized to summarize patient demographics, including means
149 \pm standard deviations (SD) for continuous variables and frequencies and percentages
150 for categorical variables. A cross-sectional analysis was performed to investigate the
151 relationships between the outcomes of postponement of regular health care visits and
152 cancer screening tests/procedures/treatment with race and ethnicity, age, education,
153 and comorbidity. Chi-square tests and binary logistic regression models of the
154 outcomes of postponement and screening were used to calculate odds ratios (and 95%
155 confidence intervals) and/or P-values (≤ 0.05 was taken as statistically significant) in
156 each sex to describe these relationships using the Statistical Analysis System (SAS),
157 version 9.4. Whites were taken as the reference group when comparing associations
158 across racial and ethnic groups. For comorbidities, the reference was reporting no
159 comorbidity.

160

RESULTS

161 Table 1 presents the number of COVID-19 survey participants by various
162 characteristics. A total of 6,974 MEC members answered the baseline survey, 6,068 via
163 the online survey, and 906 via the paper survey. Fewer men (43.5%) than women
164 (56.5%) responded. 76.6% of COVID survey participants were from Hawai'i and 23.6%
165 were from Los Angeles. The survey response rate was 7.2% for men and 6.3% for
166 women. The racial/ethnic group with the highest response rates was White (13.2% for
167 men; 12% for women, followed by Japanese American (8.9; 7.4), Native Hawaiian (7.3;
168 7.5), Other (2.7; 4.5), African American (2.7; 2.8), and Latino (2.2; 2.0). In
169 Supplementary Table 1, the distribution of the MEC cohort survivors in 2019 is
170 compared with the distribution of the COVID survey participants in 2021 by race and
171 education. For both males and females, the COVID survey respondents included a
172 larger representation of Whites and Japanese Americans and a smaller representation
173 of Latinos, African Americans, and Others compared to the entire 2019 surviving cohort.
174 The proportion of the sample that was Native Hawaiians was similar to the MEC
175 survivors. For education, a greater percentage of COVID-19 survey respondents had at
176 least some college education compared to the entire 2019 surviving cohort. This pattern
177 of higher attained education was observed for each racial/ethnic group.

178 Among participants in the baseline COVID-19 survey, the most common
179 race/ethnicity reported was White (45.2% of men; 42.7% of women), followed by
180 Japanese American (34.9%; 30.3%), Latino (7.9%; 7.4%), Native Hawaiian (6.4%;
181 8.1%), African American (3.5%; 6.5%), and Other (2.0%; 4.9%). The ethnicity category
182 of Other comprised a majority of Chinese Americans (38.1%) and Filipino (36.6%). The

183 mean age and education were similar in both sexes; however, men were more often
184 smokers and alcohol drinkers and had a higher BMI than women. Women had a greater
185 mean Healthy Eating Index-2010 score than men as reported in the MEC baseline
186 questionnaire (1993-1996).

187 Overall, 78.8% of men and 84.4% of women reported making changes to their
188 lifestyle or daily activities due to COVID-19 since March 2020. Examples of activities
189 were specifically about COVID-19 prevention measures such as covering a cough or
190 sneeze, more frequent hand washing, and social distancing. Among men, 4.2% and 6.3%
191 reported drinking more and drinking less during the COVID-19 pandemic, respectively.
192 The corresponding %'s for women were 4.3 and 5.2%. Only 3.7% of men and 2.6% of
193 women were current smokers.

194 **Table 1. Demographics of Baseline COVID Survey Participants from Hawai‘i and Los**
 195 **Angeles (May-September 2020, N = 6,974)**
 196

		Male N (%) or Mean ± SD	Female N (%) or Mean ± SD
		3,034 (43.5)	3,940 (56.5)
Race/Ethnicity	White	1,371 (45.2)	1,683 (42.7)
	Japanese American	1,059 (34.9)	1,195 (30.3)
	Latino	241 (7.9)	291 (7.4)
	Native Hawaiian	194 (6.4)	320 (8.1)
	African American	107 (3.5)	257 (6.5)
	Other ^a	62 (2.0)	194 (4.9)
Age (years)	66 – 72.8	715 (23.57)	946 (24.01)
	72.8 – 74.6	787 (25.94)	1008 (25.58)
	74.6 – 77.9	796 (26.24)	979 (24.85)
	77.9 – 102	736 (24.26)	1007 (25.56)
Age (years)		76 ± 4.9	76 ± 5.3
Years of Education ^{b, c}		15.86 ± 2.1	15.48 ± 2.2
Pack Years ^{b, c} (MEC baseline 1993-1996)		8.57 ± 12.4	5.16 ± 9.9
Alcohol Intake ^{b, c} (g/day) (MEC baseline 1993-1996)		12.65 ± 20.7	5.15 ± 11.8
Number of Days an Alcoholic Beverage was Consumed in the Past 2 Weeks ^{b, c}		4.61 ± 5.6	2.83 ± 4.7
Number of Days with 5 or More Drinks Consumed on the Same Occasion in the Past 2 Weeks ^{b, c}		0.37 ± 1.8	0.07 ± 0.8
Dietary Patterns Healthy Eating Index-2010 score ^{b, c} (MEC Baseline 1993-1996)		64.95 ± 10.8	68.66 ± 10.5
Made Lifestyle and Healthcare Changes Due to COVID-19 Since March 2020 ^c		2,361 (78.8)	3,272 (84.4)
Drinking Behavior Change Due to COVID-19^c	Do Not Drink	1,185 (39.6)	2,051 (53.5)
	Drink More	125 (4.2)	163 (4.3)
	Drink Less	189 (6.3)	199 (5.2)
	Same	1,492 (49.9)	1,421 (37.1)
	BMI (kg/m ²) ^{b, c}	26.8 ± 4.6	25.9 ± 5.8
Smoking Status^c	Never	1,320 (44.0)	2,275 (58.7)
	Not currently, but in the past	1,568 (52.3)	1,505 (38.8)
	Yes	110 (3.7)	99 (2.6)
Have Healthcare Coverage^c	Yes	2,972 (99.2)	3,837 (99.2)
	I don't know / not sure	3 (0.1)	2 (0.1)
	No	21 (0.7)	28 (0.7)
Has Primary Care Provider/Physician^c		2,908 (97.0)	3,767 (97.4)

197 ^a Comprised of a majority of Chinese Americans (38.1%) and Filipino (36.6%)

198 ^b Mean ± SD; other numbers are counts (and percentages)

199 ^c For education attained, there are missing responses from 16 men and 27 women. For the other
 200 questions asked in the MEC baseline and COVID survey, the missing responses range from 35-51 for
 201 men and 57-106 for women.

202 Regarding the participant’s health status, 3.5% and 19.7% of men had health
 203 problems that require them to stay at home and limit their activities, respectively, at the
 204 time of the COVID-19 baseline survey (Supplementary Table 2). The corresponding %’s
 205 for women were 4.9 and 19.3%. In addition, the survey respondents had a wide range
 206 of comorbidities in 2020, with hypertension (48% of men; 47.1% of women) being the
 207 most prevalent, followed by diabetes (18.3%; 14.4%), and heart disease (20.8%;
 208 10.6%). Lastly, the most frequently used medication was aspirin (37.9% of men; 28.1%
 209 of women), followed by Blood Pressure Medication ending in –sartan (29.3%; 26.0%),
 210 and Blood Pressure Medication ending in -pril (25.8%, 16.4%).

211 Overall, 54.2% of men and 61.2% of women participants reported that they had
 212 to postpone their regular healthcare visits due to COVID-19. Primary care physician and
 213 dentist visits were the most frequently postponed with 858 and 954 reports for men and
 214 1,188 and 1,453 reports for women, respectively (Table 2).

215 **Table 2. Distribution for Postponing Regular Health Care Visits Due to COVID-19**
 216 **Pandemic by Sex (N = 6,974)**
 217

	Male N (%)	Female N (%)
Postponed regular health care visits	1,625 (54.2)	2,369 (61.3)
Missing	38	72
Primary care physician	858	1,188
Oncologist	54	105
Cardiologist	207	147
Endocrinologist	44	74
Dentist	954	1,453
Other	768	1416

218 Similarly, 5.7% of men and 11.0% of women reported having to postpone a
 219 cancer screening or procedure due to COVID-19 (Table 3). The screening procedure

220 the most frequently missed was mammography (n=264), followed by skin examination
221 (n=207) and colorectal cancer screening (n=114). In the past five years, 917 survey
222 participants had been diagnosed with cancer (Supplementary Table 2). Of note, 103
223 men (3.4%) and 135 women (3.4%) reported that they were currently receiving any of
224 the following cancer treatments: chemotherapy (31 men; 30 women); immunotherapy:
225 (22 and 19) and radiation therapy (16 and 8). Among cancer patients still receiving
226 treatment, 11.5% of men and 6.9% of women had to cancel at least one treatment
227 session due to COVID-19 (Table 3).

228 **Table 3. Distribution for Postponing Cancer Screening Test/Procedure/Treatment Due to**
 229 **COVID-19 Pandemic by Demographics and Comorbidities (N = 6,974)**
 230

	Male N (%)	Female N (%)
Postponed any cancer screening test/procedure	169 (5.7)	422 (11.0)
Missing	48	87
Breast cancer screening (e.g., mammography, breast MRI)	-	264
Colorectal cancer screening (e.g., FOBT test, FIT test, colonoscopy, sigmoidoscopy)	42	72
Skin cancer screening (e.g., skin exam)	83	124
Prostate cancer screening (digital rectal examination, PSA)	25	-
Cervical cancer screening (e.g., PAP smear, pelvic exam)*	-	18
Imaging (e.g., CAT scan, DEXA, MRI)*	12	24
Other	24	29
Currently on chemotherapy, immunotherapy, or radiation therapy for cancer	103 (3.4)	135 (3.4)
Chemotherapy	31	30
Immunotherapy	22	19
Radiation Therapy	16	8
Postponed any cancer therapy session(s)	7 (11.5)	4 (6.9)
Missing	2973	3882

231 *Categories created by sorting text responses in the “Other Specify” answer choice.

232 Compared to White men, Native Hawaiian men were 41% (95% CI: 0.42, 0.84;
233 $p=0.003$) and Other men were 56% (95% CI: 0.25, 0.78, $p=0.004$) less likely, and
234 African American men were 154% (95% CI: 1.30, 4.99; $p=0.007$) more likely, to make
235 any changes to their lifestyle or daily activities, such as covering a cough or sneeze,
236 more frequent hand washing, and social distancing, since the COVID-19 pandemic
237 (Table 4). Compared to White women, Native Hawaiian women were 56% (95% CI:
238 0.33, 0.60; $p<.0001$) and Other women were 38% (95% CI: 0.41, 0.92; $p=0.02$) less
239 likely, to make any changes to their lifestyle or daily activities since the COVID-19
240 pandemic.

241 Each additional year of age was associated with less likelihood to make any
242 changes to their lifestyle or daily activities by 2% per year of age for men (OR=0.98, 95%
243 CI: 0.96, 1.00; $p=0.02$) and by 3% per year of age for women (OR=0.97, 95% CI: 0.96,
244 0.99; $p=0.0005$) (Table 4). Compared to men, women were 62% (95% CI: 1.42, 1.84;
245 $p<.0001$) more likely to make any changes to their lifestyle or daily activities. Each
246 additional year of education was associated with more likelihood to make changes to
247 their lifestyle or daily activities, by 12% per year of education in men (OR=1.12, 95% CI:
248 1.07, 1.17; $p<.0001$), and by 10% per year in women (OR=1.10, 95% CI: 1.06, 1.15;
249 $p<.0001$)

250 Compared to men with no comorbidity, men with heart disease were 41% (95%
251 CI: 1.11, 1.80; $p=0.006$), those with hypertension 34% (95% CI: 1.11, 1.62; $p=0.002$),
252 and those with lung disease, COPD, or asthma 41% (95% CI: 1.01, 1.96; $p=0.04$), more
253 likely to make changes to their lifestyle or daily activities (Table 4). Compared to women
254 with no comorbidity, women with hypertension were 21% (95% CI: 1.00, 1.47; $p=0.05$),

255 and those with lung disease, COPD, or asthma 65% (95% CI: 0.70, 1.76; p=0.001),
256 more likely to make changes to their lifestyle or daily activities.

257 **Table 4. Odds Ratio* for Change in Lifestyle or Daily Activities Since Onset of COVID-19 Pandemic by Demographics and**
 258 **Comorbidities**
 259

	Male (N = 3,000)			Female (N = 3,890)		
	Yes (n)	Odds Ratio (95% CI)	P-Value	Yes (n)	Odds Ratio (95% CI)	P-Value
Ethnicity						
White (N = 3,031)	1,083	1.00 (Ref)		1,448	1.00 (Ref)	
Japanese American (N = 2,228)	833	1.02 (0.83,1.26)	0.83	994	0.86 (0.69,1.07)	0.17
Latino (N = 520)	177	0.99 (0.70,1.40)	0.96	233	0.94 (0.65,1.35)	0.73
Native Hawaiian (N = 509)	135	0.59 (0.42,0.84)	0.003	235	0.44 (0.33,0.60)	<.0001
African American (N = 354)	96	2.54 (1.30,4.99)	0.01	211	0.96 (0.64,1.43)	0.82
Other (N = 248)	37	0.44 (0.25,0.78)	0.01	151	0.62 (0.41,0.92)	0.02
Age (Years) (N = 6,890)	2,361	0.98 (0.96,1.00)	0.02	3,272	0.97 (0.96,0.99)	0.001
Maximum Education Obtained (Years) (N = 6,847)	2,347	1.12 (1.07,1.17)	<.0001	3,248	1.10 (1.06,1.15)	<.0001
Comorbidities						
None (N=2,307)**	694	1.00 (Ref)		1,140	1.00 (Ref)	
Heart Disease (N = 1,035)	51	1.41 (1.11,1.80)	0.01	356	1.19 (0.86,1.63)	0.29
Hypertension (N = 3,271)	1,169	1.34 (1.11,1.62)	0.002	1,545	1.21 (1.00,1.47)	0.05
Diabetes (N = 1,106)	424	0.87 (0.68,1.10)	0.25	462	0.90 (0.69,1.16)	0.40
Lung Disease, COPD, or Asthma (N = 819)	249	1.41 (1.01,1.96)	0.04	466	1.65 (1.22,2.23)	0.001
Kidney Disease (N = 340)	138	1.37 (0.87,2.13)	0.17	150	1.11 (0.70,1.76)	0.65
Diagnosed w/ Cancer in past 5 yrs. (N = 921)	383	1.09 (0.84,1.40)	0.51	383	1.21 (0.89,1.64)	0.22

260 *Adjusted for the other variables in the table.

261 *Male (Reference) vs. Female: OR = 1.62 (95% CI: 1.42,1.84; p<.0001)

262 **Number of respondents who did not answer affirmatively for any listed co-morbidities.

263

264 Similarly, compared to White men, Latino men were 26% (95% CI: 0.55, 0.99;
265 $p=0.04$) and Native Hawaiian men 36% (95% CI: 0.47, 0.88; $p=0.005$) less likely to
266 postpone regular health care visits due to the COVID-19 pandemic (Table 5). Compared
267 to White women, Native Hawaiian women were 40% (95% CI: 0.47, 0.78; $p=0.0001$)
268 less likely to postpone regular healthcare visits due to the COVID-19 pandemic.

269 Each additional year of age in women was associated with a lower likelihood to
270 postpone regular healthcare visits by 2% per year (OR=0.98, 95% CI: 0.97, 0.99;
271 $p=0.0006$) (Table 5). Each additional year of education in men was associated with a
272 higher likelihood to postpone regular health care visits, by 45% per year (OR=1.04, 95%
273 CI: 1.00, 1.08; $p=0.04$). Compared to men, women were 43% (95% CI: 1.29, 1.58;
274 $p<.0001$) more likely to postpone regular health care visits.

275 Compared to men with no comorbidity, men with heart disease were 37% (95%
276 CI: 1.13, 1.65; $p=0.0011$) more likely to postpone regular health care visits (Table 5).
277 Compared to women with no comorbidity, women with hypertension were 16% (95% CI:
278 1.00, 1.33; $p=0.04$), those with kidney disease 49% (95% CI: 1.05, 2.11; $p=0.03$), and
279 those diagnosed with cancer in the past 5 years 51% (95% CI: 1.21, 1.88; $p=0.0003$),
280 more likely to postpone regular health care visits.

281 **Table 5. Odds Ratio* for Postponing Regular Health Care Visits Due to COVID-19 Pandemic by Demographics and**
 282 **Comorbidities**
 283

	Male (N = 2,998)			Female (N = 3,881)		
	Yes (n)	Odds Ratio (95% CI)	P-Value	Yes (n)	Odds Ratio (95% CI)	P-Value
Ethnicity						
White (N = 3,026)	770	1.00 (Ref)		1,042	1.00 (Ref)	
Japanese American (N = 2,224)	560	0.88 (0.74,1.04)	0.13	715	0.93 (0.80,1.09)	0.38
Latino (N = 519)	114	0.74 (0.55,0.99)	0.04	187	1.32 (0.99,1.76)	0.06
Native Hawaiian (N = 508)	88	0.64 (0.47,0.88)	0.005	163	0.60 (0.47,0.78)	0.0001
African American (N = 354)	61	1.01 (0.67,1.52)	0.98	155	1.01 (0.75,1.34)	0.97
Other (N = 248)	32	0.87 (0.51,1.49)	0.62	107	0.77 (0.56,1.05)	0.10
Age (Years) (N = 6,879)	1,625	1.00 (0.99,1.02)	0.85	2,369	0.98 (0.97,0.99)	0.001
Maximum Education Obtained (Years) (N = 6,836)	1,617	1.04 (1.00,1.08)	0.04	2,354	1.03 (1.00,1.06)	0.10
Comorbidities						
None (N=2,301)**	445	1.00 (Ref)		800	1.00 (Ref)	
Heart Disease (N =1,032)	382	1.37 (1.13,1.65)	0.001	266	1.18 (0.94,1.49)	0.16
Hypertension (N = 3,266)	819	1.16 (1.00,1.35)	0.06	1,141	1.16 (1.00,1.33)	0.04
Diabetes (N = 1,106)	314	1.15 (0.94,1.40)	0.18	346	1.00 (0.82,1.22)	1.00
Lung Disease, COPD, or Asthma (N = 821)	179	1.25 (0.98,1.61)	0.08	335	1.12 (0.92,1.36)	0.26
Kidney Disease (N = 339)	100	1.16 (0.83,1.62)	0.40	123	1.49 (1.05,2.11)	0.03
Diagnosed w/ Cancer in past 5 yrs. (N = 920)	268	1.04 (0.85,1.27)	0.73	305	1.51 (1.21,1.88)	0.0003

284 *Adjusted for the other variables in the table.
 285 *Male (Reference) vs. Female: OR = 1.43 (95% CI: 1.29,1.58; p<.0001)
 286 **Number of respondents who did not answer affirmatively for any listed co-morbidities.

287 Compared to White men, Japanese American men were 72% (95% CI: 0.18,
288 0.45; $p < .0001$) less likely to postpone any cancer screening test/procedure due to the
289 COVID-19 pandemic (Table 6). Compared to White women, Japanese American
290 women were 40% (95% CI: 0.46, 0.78; $p = 0.0002$) less likely to postpone any cancer
291 screening test/procedure due to the COVID-19 pandemic.

292 Women were 4% less likely for each additional year of age (95% CI: 0.94, 0.98;
293 $p = 0.001$) to postpone any cancer screening test/procedure (Table 6). Women were 10%
294 more likely for each additional year of education (95% CI: 1.05, 1.16; $p = 0.0004$) to
295 postpone any cancer screening test/procedure. Compared to men, women were 137%
296 (95% CI: 1.95, 2.88; $p < .0001$) more likely to postpone any cancer screening
297 test/procedure.

298 Compared to men with no comorbidity, men diagnosed with cancer in the past 5
299 years were 254% (95% CI: 2.52, 4.95; $p < .0001$) more likely to postpone any cancer
300 screening test/procedure (Table 6). Compared to women with no comorbidity, women
301 with lung disease, COPD, or asthma were 50% (95% CI: 1.14, 1.98; $p = 0.004$) and those
302 diagnosed with cancer in the past 5 years were 222% (95% CI: 2.50, 4.14; $p < .0001$)
303 more likely to postpone any cancer screening test/procedure.

304 **Table 6. Odds Ratio* for Postponing Cancer Screening Test/Procedure Due to COVID-19 Pandemic by Demographics and**
 305 **Comorbidities**
 306

	Male (N = 2,988)			Female (N = 3,866)		
	Yes (n)	Odds Ratio (95% CI)	P-Value	Yes (n)	Odds Ratio (95% CI)	P-Value
Ethnicity						
White (N = 3,018)	123	1.00 (Ref)		227	1.00 (Ref)	
Japanese American (N = 2,220)	23	0.28 (0.18,0.45)	<.0001	90	0.60 (0.46,0.78)	0.0002
Native Hawaiian (N = 508)	7	0.48 (0.21,1.05)	0.07	32	0.73 (0.48,1.11)	0.14
African American (N = 353)	7	0.90 (0.40,2.03)	0.81	27	1.01 (0.65,1.57)	0.96
Latino (N = 509)	8	0.48 (0.23,1.03)	0.06	25	0.90 (0.57,1.44)	0.66
Other	1	0.24 (0.03,1.80)	0.17	21	0.86 (0.53,1.41)	0.55
Age (Years) (N = 6,854)	169	0.96 (0.93,1.00)	0.06	422	0.96 (0.94,0.98)	0.001
Maximum Education Obtained (Years) (N = 6,811)	166	1.03 (0.95,1.12)	0.50	421	1.10 (1.05,1.16)	0.0004
Comorbidities						
None (N=2,295)**	47	1.00 (Ref)		121	1.00 (Ref)	
Heart Disease (N = 1,028)	29	0.82 (0.53,1.27)	0.37	52	1.21 (0.87,1.69)	0.27
Hypertension (N = 3,255)	75	1.07 (0.76,1.50)	0.70	195	1.07 (0.86,1.34)	0.56
Diabetes (N = 1,099)	22	0.88 (0.54,1.44)	0.61	53	0.83 (0.59,1.16)	0.27
Lung Disease, COPD, or Asthma (N = 815)	17	0.84 (0.48,1.47)	0.54	79	1.50 (1.14,1.98)	0.004
Kidney Disease (N = 337)	7	0.89 (0.40,2.00)	0.78	18	0.94 (0.55,1.58)	0.80
Diagnosed w/ Cancer in past 5 yrs. (N = 918)	71	3.54 (2.52,4.95)	<.0001	112	3.22 (2.50,4.14)	<.0001

307 *Adjusted for the other variables in the table.

308 *Male (Reference) vs. Female: OR = 2.37 (95% CI: 1.95,2.88; p<.0001)

309 **Number of respondents who did not answer affirmatively for any listed co-morbidities.

310

DISCUSSION

311 The results of this study suggest unique relationships between participant
312 characteristics, such as sex, age, years of education, race/ethnicity, and comorbidities
313 with the likelihood of making changes to lifestyle or daily activities and of postponing
314 regular health care visits and cancer screenings/treatments during the COVID-19
315 pandemic. Responses were compared between males and females and by
316 race/ethnicity to describe the differences between these groups.

317 African American men (compared to White men), women (compared to men),
318 men and women with more education, men and women with heart disease,
319 hypertension, or lung disease, COPD, or asthma (compared to men or women with no
320 comorbidity) were more likely to make changes to their lifestyle or daily activities during
321 the COVID-19 pandemic. As expected, participants with one or more risk factors, such
322 as cancer or lung disease, were more likely to make changes to their lifestyle during the
323 pandemic as they were reported to be at increased risk of severe illness from COVID-19.

324 Men with more education, women (compared to men), men with heart disease,
325 and women with hypertension, kidney disease, and diagnosed with cancer in the past 5
326 years were more likely to postpone regular health care visits. As expected, participants
327 with comorbidity were more likely to postpone healthcare visits, as they were
328 recommended to avoid public places to protect themselves from the virus.

329 Lastly, women with more education, women (compared to men), women and
330 men diagnosed with cancer in the past 5 years, and women with lung disease, COPD,
331 or asthma were more likely to postpone any cancer screening test/procedure.

332 Native Hawaiian men and women and those of Other race/ethnicity (compared to
333 White men or women), and older men and women were less likely to make changes to
334 their lifestyle or daily activities during the COVID-19 pandemic. Latino and Native
335 Hawaiian men, Native Hawaiian women, and older women were less likely to postpone
336 regular healthcare visits during the COVID-19 pandemic. Lastly, Japanese American
337 men and women and older women were less likely to postpone any cancer screening
338 test/procedure during the COVID-19 pandemic.

339 **Effect on Healthcare Visits**

340 From May 2020 to September 2020, 54.2% of male and 61.3% of female MEC
341 survey respondents reported postponing regular health care visits. These numbers are
342 consistent with a report published by The Commonwealth Fund in May 2020.¹³ In the
343 U.S., early in the pandemic from February 2020, the number of visits to ambulatory care
344 practice declined by nearly 60%.¹³ Declines in visits varied by geographic area and
345 clinical specialty. By April 2020, a rebound of in-person visits had occurred and appears
346 largest in the South Central (East and West) census division (Texas, Oklahoma,
347 Arkansas, Louisiana, Mississippi, Alabama, Tennessee, and Kentucky) but the number
348 of visits was still roughly one-third lower than before the pandemic. As in-person visits
349 declined, telehealth visits increased rapidly before plateauing. By mid-May 2020, a
350 rebound in visits had occurred across all specialties. But the relative decline in visits
351 remained largest among surgical and procedural specialties and pediatrics. The greater
352 effect on surgical and procedural specialties was observed in the MEC survey
353 responses, as visits with eye specialists, dermatologists, cardiologists, and dentists,
354 were more often reported to be postponed. In the Commonwealth Fund study, the

355 relative decline was smaller in other specialties, such as adult primary care. The MEC
356 study findings differ as visits for this specialty were the most frequently postponed in our
357 data. In addition, researchers from Harvard Medical School examined the trends in
358 outpatient care delivery and telemedicine in a cohort of 16,740,365 enrollees captured
359 from the OptumLabs Data Warehouse. The weekly rate of telemedicine visits increased
360 during the pandemic period starting from January 1, 2020, and peaking in the week of
361 April 15, 2020, before declining by the week of June 10, 2020. By the last 4 weeks of
362 the study period, May 20 through June 16, Hawai'i had a -73.2% change and California
363 had a -31.0% change from baseline in weekly total visits per 1000 members. For visits
364 delivered via telemedicine, Hawai'i had a 24.5% increase from baseline and California
365 had a 29.5% increase.¹⁴ Although the COVID-19 pandemic led to widespread
366 disruptions in medical care, it is possible that patients who avoided hospital visits had a
367 positive outcome of lower risk of catching COVID-19. There may have been some
368 benefit to the strategy of keeping patients out of the hospitals and physician offices. In
369 the baseline MEC COVID Survey, only 49 men and 68 women, overall, reported an
370 episode of COVID-19.

371 The likelihood of postponing healthcare visits being related to the presence of
372 comorbidities was also investigated. In the MEC Survey, men with heart disease (by
373 37%), women with hypertension (by 16%), kidney disease (by 49%), and those
374 diagnosed with cancer in the past 5 years (by 51%) were more likely to postpone
375 regular health care visits due to the COVID-19 pandemic. These findings were
376 consistent with a study that examined factors associated with postponed health
377 checkups during the COVID-19 pandemic in Germany.¹⁵ Researchers found the

378 probability of postponed health checkups was positively associated with the presence of
379 chronic disease (OR: 1.68, 95% CI: 1.15, 2.47), higher concern for a COVID-19
380 infection (OR: 1.44, 95% CI: 1.16, 1.78), and higher presumed severity of COVID-19
381 (OR: 1.17, 95% CI: 1.01, 1.35).

382 **Effect on Cancer Screening**

383 Not many MEC survey respondents reported postponing a cancer screening test
384 or procedure due to COVID-19. Only 5.7% of men and 11.0% of women did so. These
385 numbers were lower than expected but could be explained by the older age of our
386 sample. The recommended cut-off age for breast and colorectal cancer screening is 75
387 years old. Half of the respondents were aged 75 and older. However, when focusing on
388 participants 75 years and younger, the numbers were similar to the overall sample size:
389 6.1% vs. 5.7% of men overall and 12.3% vs. 11.0% of women overall. The screening
390 procedure the most frequently missed was mammography, followed by skin
391 examination and colorectal cancer screening. Postponement of these cancer screening
392 procedures is consistent with data from a published study looking at a sample of health
393 claims clearinghouse records from 18 states containing 184 million claims from 30
394 million patients in 2019 and 94 million claims from 20 million patients for the first 6
395 months in 2020.¹⁶ Mammograms and Pap smears were down nearly 80 percent in April
396 2020 compared to 2019. However, numbers for both services recovered throughout the
397 summer and fall, with Pap smears and mammograms rebounding above 2019 levels in
398 August 2020 and November 2020, respectively. Colonoscopies were down almost 90%
399 in mid-April 2020, compared to 2019, and in December 2020 were still down about 15%
400 compared to the previous year, representing a substantial but incomplete rebound in

401 care delivered. The overall number of colonoscopies performed in 2020 declined by
402 almost 25% from 2019.

403 The likelihood of postponing cancer screenings was also analyzed in relation to
404 age. In the MEC study, women with each additional year of age were less likely by 4%
405 per year of age (OR=0.96, 95% CI: 1.00, 1.08; p=0.04) to postpone any cancer
406 screening test/procedure. This finding is consistent with a study examining determinants
407 of postponed cancer screening during the COVID-19 pandemic in Germany.¹⁷ Multiple
408 logistic regressions were conducted with postponed cancer screenings since March
409 2020 due to the COVID-19 pandemic as the outcome measure (0= no, attended as
410 planned, 1 = postponed). Regressions revealed that the likelihood of postponing cancer
411 screening was positively associated or more likely with higher concern for a COVID-19
412 infection (OR: 1.65, 95% CI: 1.16, 2.35), whereas it was negatively associated or less
413 likely with older age (e.g., 65 years and over, OR: 0.38, 95% CI: 0.16, 0.89, compared
414 to individuals 30 to 49 years).

415 The backlog of postponed or delayed cancer screenings will have a long-term
416 clinical impact and potentially increase the cancer burden. A study from Canada
417 examined the impact of episodic screening interruptions for breast and colorectal
418 cancer.¹⁸ Using a simulation model, researchers projected a surge of cancer cases
419 when screening resumes. For breast cancer screening, the simulation model suggests
420 that a three-month interruption of breast cancer screening due to COVID-19 would
421 result in 644,000 fewer screens being performed in Canada in 2020. A three-month
422 interruption starting in 2020 could increase cases diagnosed at advanced stages (310
423 more) and breast cancer deaths (110 more) in Canada from 2020 to 2029. A six-month

424 interruption starting in 2020 could lead to 670 extra advanced breast cancers and 250
425 additional breast cancer deaths in Canada from 2020 to 2029. For colorectal cancers,
426 without service interruption, the simulation model estimated that 68,000 colonoscopies
427 would have been performed in the six months since March 2020 in Canada. A six-
428 month suspension of primary screening could increase cancer incidence by 2,200 cases
429 with 960 more cancer deaths over the lifetime. Longer interruptions, and reduced
430 volumes of patients when screening resumes, would further increase excess cancer
431 deaths. Since cancer diagnoses and deaths in the MEC are identified through linkages
432 to cancer registries in HI and California, we will be able to examine whether a greater
433 proportion of cancers were diagnosed at a late stage in the aftermath of the pandemic
434 and investigate any differences among ethnic/racial groups. Similarly, through the
435 linkage of the cohort to Medicare, we will be able to identify MEC members who
436 developed COVID-19 and investigate long-term complications and survival across age
437 and race.

438 **Limitations**

439 There are several limitations to our study. Although our study population is
440 diverse, some subgroups of race/ethnicity (African Americans and Latinos) were under-
441 represented compared to other subgroups. Additionally, the study sample is not fully
442 representative of the entire MEC cohort, as the participants were more educated with
443 higher percentages with at least some college education across all races/ethnicities.
444 The survey respondents included a larger representation of Whites and Japanese
445 Americans and a smaller representation of Latinos and African Americans compared to
446 the MEC survivors in 2019. The effect of COVID-19 on cervical cancer screening was

447 not investigated due to the older age of our participants. The data was self-reported so
448 there is a chance of misclassification due to recall error. Lastly, the response rates were
449 low across all races/ethnicities, and only 0.9% of male and 1.7% of female survey
450 participants are living in a retirement or care home so these populations were most
451 certainly underrepresented.

452 **CONCLUSION**

453 The MEC COVID-19 survey demonstrated the possibility of using a mature
454 cohort study of well-characterized individuals to characterize the effect of a public health
455 emergency. The study revealed associations of factors like sex, race/ethnicity, age,
456 education level, and comorbidities with cancer-related screening and healthcare among
457 MEC participants during the COVID-19 pandemic in Hawai'i and Los Angeles. The MEC
458 COVID-19 survey results were consistent with other studies regarding the
459 postponement of healthcare visits, surgical procedures, and cancer screenings during
460 the pandemic. In the wake of the pandemic, increased monitoring of patients in high-risk
461 groups for cancer and other diseases is of the utmost importance as the chance of
462 undiagnosed cases and poor prognosis due to delayed screening and/or treatment
463 increases.


464

465

APPENDIX

466 Supplementary Tables and Figure

467 **Supplementary Figure 1. Timeline of the MEC COVID-19 Study**



468

06/16/20

469
470
471

Supplementary Table 1. Comparison of Ethnicity and Educational Level between 2019 MEC Cohort Survivors and 2021 COVID Survey Participants

Ethnicity	(%)		Educational Level (%)							
	2019 MEC Cohort (N = 111,433)	COVID Survey Cohort (N = 6,974)	≤8 years		9–12 years		Vocational		At least some college	
Male and Female			MEC	COVID	MEC	COVID	MEC	COVID	MEC	COVID
White	23.1	43.8	1.7	0	18.8	6.8	4.3	2.4	75.2	90.8
Japanese American	28.2	32.3	1.3	0.1	27.4	7.0	13.8	9.0	57.5	83.9
Latino	23.6	7.6	35.3	8.1	30.9	20.4	6.8	5.9	27.0	65.6
Native Hawaiian	6.7	7.4	1.3	0.2	42.3	21.1	9.4	8.2	47.0	70.5
African-American	11.7	5.2	3.5	0	28.0	10.0	6.1	3.3	62.4	86.7
Other	6.7	3.7	10.0	0.4	22.3	10.6	6.9	4.7	60.8	84.3

472 **Supplementary Table 2. Distribution of Baseline COVID Survey Participants by**
 473 **Health Status, Comorbidities, and Medication Use, Hawai'i and Los Angeles (N =**
 474 **6,974)**
 475

	Male N (%)	Female N (%)
Health Status:		
Has Health Problems that Require Them to Stay at Home	104 (3.5)	189 (4.9)
Missing	35	64
Needs Assistance with Daily Living Activities on a Regular Basis	96 (3.2)	156 (4.0)
Missing	35	61
Cane, Walker, or Wheelchair/Scooter Usage to Get About	193 (6.4)	363 (9.4)
Missing	36	57
History of Health Problems that Limit Activities	591 (19.7)	747 (19.3)
Missing	36	62
Comorbidities		
History of Heart Disease	622 (20.8)	412 (10.6)
Missing	38	69
History of Hypertension	1,441 (48.0)	1,824 (47.1)
Missing	37	63
History of Diabetes	548 (18.3)	559 (14.4)
Missing	35	63
History of Lung Disease, COPD, or Asthma	297 (9.9)	523 (13.5)
Missing	37	67
History of Kidney Disease	164 (5.5)	175 (4.5)
Missing	36	65
Diagnosed with Cancer in the Past 5 Years	478 (15.9)	439 (11.3)
Missing	35	62

476
477

478 **Supplementary Table 2. (Continued)**
 479

Medication Use		
Taking immunosuppressant medications (including steroids, methotrexate, biologic agents)	110 (3.7)	182 (4.7)
Missing	44	78
Taking heartburn medication Pepsid (famotidine)	307 (10.3)	383 (9.9)
Missing	39	64
Taking Aspirin (baby aspirin or std dose)	1,135 (37.9)	1,091 (28.1)
Missing	36	59
Taking NSAIDs like ibuprofen, nurofen, diclofenac, naproxen	267 (8.9)	418 (10.8)
Missing	35	65
Taking Blood Thinning Medication (such as Coumadin/Warfarin, Eliquis/apixaban)	480 (16.0)	293 (7.6)
Missing	42	75
Taking Blood Pressure Medication ending in -pril (such as enalapril, lisinopril, captopril, ramipril)	771 (25.8)	632 (16.4)
Missing	46	84
Taking Blood Pressure Medication ending in -sartan (such as losartan valsartan, irbesartan)	874 (29.3)	1,004 (26.0)
Missing	46	83

480

481

482

483

484 **Supplementary Table 3. Distribution for Postponing Regular Health Care Visits**
 485 **Due to COVID-19 Pandemic by Sex (N = 6,974)**
 486

	Male N (%)	Female N (%)
Other*:	768	1416
Dermatology	156	218
Eye	248	411
ENT	44	67
OB-GYN	0	105
Orthopedist	36	62
Podiatrist	31	39
Urologist	70	27
Neurologist	27	28
Rheumatologist	15	50
Pulmonologist	19	35
Audiologist	24	50
Allergist	2	15
Gastroenterologist	5	10
Laboratory Testing/Imaging	21	140
Physical/Massage/Chiropractic Therapy	34	89
Other specialists	15	23
Other healthcare providers	21	47

487 *All other categories were sorted from the text responses for specifying the “Other specialist or health
 488 care provider.”

REFERENCES

- 489
490
- 491 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real
492 time. *Lancet Infect Dis.* 2020;20(5):533-534. doi:10.1016/S1473-3099(20)30120-1

 - 493 2. Coronavirus disease (COVID-19): Risks and safety for older people. World Health
494 Organization. Accessed November 11, 2020. [https://www.who.int/news-room/questions-and-](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-risks-and-safety-for-older-people)
495 [answers/item/coronavirus-disease-covid-19-risks-and-safety-for-older-people](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-risks-and-safety-for-older-people)

 - 496 3. Schmidt AL, Bakouny Z, Bhalla S, Steinharter JA, Tremblay DA, Awad MM, Kessler AJ,
497 Haddad RI, et al. Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and
498 Cancer Outcomes Study. *Cancer Cell.* 2020;38(6):769-770. doi:10.1016/j.ccell.2020.10.023

 - 499 4. Newman LA, Winn RA, Carethers JM. Similarities in Risk for COVID-19 and Cancer
500 Disparities. *Clin Cancer Res.* 2021;27(1):24-27. doi:10.1158/1078-0432.CCR-20-3421

 - 501 5. Corley DA, Sedki M, Ritzwoller DP, Greenlee RT, Neslund-Dudas C, Rendle KA, Honda
502 SA, Schottinger JE, et al. Cancer Screening During the Coronavirus Disease-2019 Pandemic:
503 A Perspective From the National Cancer Institute's PROSPR Consortium. *Gastroenterology.*
504 2021;160(4):999-1002. doi:10.1053/j.gastro.2020.10.030

 - 505 6. Nodora JN, Gupta S, Howard N, Motadel K, Propst T, Rodriguez J, Schultz J, Velasquez S,
506 et al. The COVID-19 Pandemic: Identifying Adaptive Solutions for Colorectal Cancer
507 Screening in Underserved Communities. *JNCI J Natl Cancer Inst.* 2021;113(8):962-968.
508 doi:10.1093/jnci/djaa117

 - 509 7. London JW, Fazio-Eynullayeva E, Palchuk MB, Sankey P, McNair C. Effects of the
510 COVID-19 Pandemic on Cancer-Related Patient Encounters. *JCO Clin Cancer Inform.*
511 2020;(4):657-665. doi:10.1200/CCI.20.00068

 - 512 8. Pike MC, Kolonel LN, Henderson BE, Wilkens LR, Hankin JH, Feigelson HS, Wan PC,
513 Stram DO, Nomura AMY. Breast cancer in a multiethnic cohort in Hawaii and Los Angeles:
514 risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites.
515 *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev*
516 *Oncol.* 2002;11(9):795-800.

 - 517 9. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin.* 2020;70(1):7-30.
518 doi:10.3322/caac.21590

 - 519 10. Damiani G, Basso D, Acampora A, Bianchi CBNA, Silvestrini G, Frisicale EM, Sassi F,
520 Ricciardi W. The impact of level of education on adherence to breast and cervical cancer
521 screening: Evidence from a systematic review and meta-analysis. *Prev Med.* 2015;81:281-
522 289. doi:10.1016/j.ypmed.2015.09.011

 - 523 11. Rodriguez N, Smith J. The Association Between Education and Colorectal Cancer Screening
524 among United States Veterans Aged 50-75 Years Old: 286. *Off J Am Coll Gastroenterol*
525 *ACG.* 2016;111:S134.

- 526 12. Kolonel LN, Henderson BE, Hankin JH, Nomura AMY, Wilkens LR, Pike MC, Stram DO,
527 Monroe KR, et al. A Multiethnic Cohort in Hawaii and Los Angeles: Baseline
528 Characteristics. *Am J Epidemiol*. 2000;151(4):346-357.
529 doi:10.1093/oxfordjournals.aje.a010213
- 530 13. Mehrotra A, Chernew M, Linetsky D, Hatch H, Cutler D. The impact of the COVID-19
531 pandemic on outpatient visits: a rebound emerges. *Commonwealth Fund*. Published online
532 2020. doi:10.26099/DS9E-JM36
- 533 14. Patel SY, Mehrotra A, Huskamp HA, Uscher-Pines L, Ganguli I, Barnett ML. Trends in
534 Outpatient Care Delivery and Telemedicine During the COVID-19 Pandemic in the US.
535 *JAMA Intern Med*. 2021;181(3):388-391. doi:10.1001/jamainternmed.2020.5928
- 536 15. Hajek A, De Bock F, Kretzler B, König HH. Factors associated with postponed health
537 checkups during the COVID-19 pandemic in Germany. *Public Health*. 2021;194:36-41.
538 doi:10.1016/j.puhe.2021.02.023
- 539 16. Martin K, Kurowski D, Given P, Kennedy K, Clayton E. The Impact of COVID-19 on the
540 Use of Preventive Health Care. HCCI. Accessed March 15, 2022.
541 [https://healthcostinstitute.org/hcci-research/the-impact-of-covid-19-on-the-use-of-](https://healthcostinstitute.org/hcci-research/the-impact-of-covid-19-on-the-use-of-preventive-health-care)
542 [preventive-health-care](https://healthcostinstitute.org/hcci-research/the-impact-of-covid-19-on-the-use-of-preventive-health-care)
- 543 17. Hajek A, De Bock F, Huebl L, Kretzler B, König HH. Determinants of Postponed Cancer
544 Screening During the COVID-19 Pandemic: Evidence from the Nationally Representative
545 COVID-19 Snapshot Monitoring in Germany (COSMO). *Risk Manag Healthc Policy*.
546 2021;Volume 14:3003-3011. doi:10.2147/RMHP.S297326
- 547 18. Yong JH, Mainprize JG, Yaffe MJ, Ruan Y, Poirier AE, Coldman A, Nadeau C, Iragorri N,
548 et al. The impact of episodic screening interruption: COVID-19 and population-based cancer
549 screening in Canada. *J Med Screen*. 2021;28(2):100-107. doi:10.1177/0969141320974711
- 550

COVID-19 SYMPTOM TRACKER APP

ONLINE BASELINE QX

ONLINE FOLLOW-UP QX

